Clinical Trial Search

Primary: Progression-Free Survival (PFS) in ERBB2-Negative Tumors Compared to ERBB2-Positive Tumors — 79.2; 83.3; 69.6; 86.7 probability of PFS at 2 years — p=0.8001

Primary: Progression-free Survival (PFS) — 52.0 percent probability

Primary: 12 Month Progression-free Survival (PFS-12) — 215; 69 Days — p=0.927

Primary: Objective Response (CR+PR) Sustained for ≥ 8 Weeks — 0; 0.15; 0 proportion of participants

Primary: Event-free Survival — 7 Participants

Primary: Number of Patients Who Have Either a Complete Response (CR) Rate or No Complete Response Rate — 13; 15; 16; 15 Participants — p=0.35

Primary: Objective Response (CR+PR) Sustained for ≥ 8 Weeks — 1 participants

Primary: Percentage of Participants With an Objective Response and Long-term Stable Disease — 0; 11.1; 10.5; 0 percentage of participants

Primary: Overall Survival — 2.43; 13.6 percent probability

Primary: Overall Response Rate [Complete Response + Very Good Partial Response + Partial Response (CR + VGPR + PR)] — 42 Participants

Primary: Number of Patients Who Experienced Dose-limiting Toxicities (DLTs) — 3 Participants

Primary: Number of Participants With Dose-limiting Toxicities (DLT) in Phase I — 0; 1; 0; 0 participants

Primary: Event-free Survival (EFS) — 76.3; 84.9; 85.8; 85.8 probability of 3 year EFS

Primary: Feasibility

Primary: Therapy Completion Rate — .40 proportion of participants

Primary: Cumulative Incidence of Ototoxicity — 12; 16; 16; 15 percentage of participants

Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 14 participants

Primary: Percentage of Participants With Objective Response of Complete Response or Partial Response — 32.6; 0 percentage of participants

Primary: Number of Participants With High-grade Astrocytoma and Diffuse Pontine Tumors Achieving One Year Progression Free Survival. — 5; 6 Participants

Primary: Percentage of Patients for Whom 3 or More Vaccines Can be Made — 90.9 percentage of participants

Primary: Percentage of Participants With Overall Response Rate (ORR) According to Independent Review Committee (IRC) From Date First Participant Randomized, 13-Sep-2013 to Date…

Primary: Response (Complete Response, Very Good Partial Response, and Partial Response) at 60-days Post Stem Cell Infusion — 4; 3 participants

Primary: 2-year Local Recurrence Rate (LRR)/Incidence of Local Recurrence — 10 percentage of patients with LR

Primary: Two Year Survival of Pediatric Patients With Diffuse Pontine Gliomas — 14.29 Percentage of patients

Primary: Number of Participants With Local Recurrence in the Spared NPC Niches — 0 Participants

Primary: Percentage of Participants With Adverse Events (AE) Related to Treatment — 5.26; 0; 0; 21.0 percentage of participants

Primary: Proportion of Participants With Grade 3 or Higher, Treatment-related, Adverse Events — 0.142; 0.142; 0.142; 0.142 proportion of participants

Primary: Measurement of Number of Adverse Events — 4; 6; 3; 5 Adverse events

Primary: One Year Overall Survival — 0.7208 Estimated probability

Primary: Cumulative Incidence of Ototoxicity — 26; 27 percentage of participants